AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03349619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this arm will receive nasal saline solution 0.9%, two sprays per nostril, three times/day for 4 weeks
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or SC
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV or SC
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV or IT
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV or IT
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given PO
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IM or IT
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IM or IT
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IM
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IM
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study NCT01615289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 250 ml green tea extract
Description: Intragastric instillation by feeding tube
Study NCT01615289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 500 ml green tea extract
Description: Intragastric instillation by feeding tube
Study NCT01615289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Single intragastric instillation of 250 ml control solution
Description: Intragastric instillation by feeding tube
Study NCT01615289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Single intragastric instillation of 500 ml control solution
Description: Intragastric instillation by feeding tube
Study NCT01764893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PTNS plus solifenacin
Description: 12 weekly treatments with percutaneous tibial nerve stimulation with 5 mg of solifenacin; an additional 4 weeks of solifenacin for a total of 15 weeks of study drug.
Study NCT01764893 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weekly treatments with percutaneous tibial nerve stimulation with placebo; an additional 4 weeks of placebo for a total of 15 weeks of placebo.
Study NCT04115657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starch 1
Description: Consumption of milk tea with sucrose and boba pearls made from tapioca starch
Study NCT04115657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starch 2
Description: Consumption of milk tea with sucrose and boba pearls made from high amylose
Study NCT04115657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starch 3
Description: Consumption of milk tea with sucrose and boba pearls made from kithul flour
Study NCT04115657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starch 4
Description: Consumption of milk tea with sucrose and boba pearls made from sago flour
Study NCT04115657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar 1
Description: Consumption of milk tea with pure palatinose and boba pearls made from tapioca starch
Study NCT04115657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar 2
Description: Consumption of milk tea with blend of sucrose and palatinose and boba pearls made from tapioca starch
Study NCT00159263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Dry powder inhaler
Study NCT00159263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Inhalant Powder
Description: 12ug
Study NCT00159263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Powder
Description: Inhaler
Study NCT00159263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide and Formoterol Product
Description: Combination Inhaler, Symbicort
Study NCT04018274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 50 mg by mouth (PO) once daily (QD)
Study NCT04018274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE) and levonorgestrel(LN)
Description: Oral tablet containing 30 ug EE and 150 ug of LN
Study NCT04093089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionode IOP Lowering System
Description: Patients wearing Bionode spectacles and customized contact lens and will receive stimulation at 50 Hz, 100 µs, up to 150 µA for 2 hours.
Study NCT04093089 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bionode IOP Lowering System
Description: Control: No stimulation
Study NCT01038375 — intervention group
Intervention type: BEHAVIORAL
Intervention: lifestyle counseling, home blood pressure monitoring
Description: monthly telephone counseling over 6 months for intervention group no health provider initiated contact for control group
Study NCT04292704 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: the fractional CO2 laser
Description: The fractional CO2 laser therapy mechine: the wavelength is 10.6 μ m, the output power is 40 w, the action time is 2000 μ s and the lattice spacing is 700 \~ 1000 μ m
Study NCT04292704 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clotrimazole
Description: Clotrimazole vaginal tablets
Study NCT04103567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: Fecal samples collected at different times : during inclusion consultation with surgeon, after neoadjuvant treatment and before surgery.
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03081247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF 320/14.4/9.6 µg MDI
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
Study NCT03081247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF 320/9.6 µg
Description: Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
Study NCT03722706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational handbook
Description: The intervention being evaluated in this study is an educational handbook for parents of children with atopic dermatitis (AD). The handbook was developed and written by the interdisciplinary study team (psychologist, allergist, nurse practitioner, dermatologists, primary care physician, dietitian). Content was based on practice guidelines for AD management, consensus recommendations for therapeutic patient education for AD, and clinical experience of our study team. Content includes topics central to effective AD management, such as pathophysiology/course, elements of treatment plans, and strategies to improve quality of life, such as breaking the itch-scratch cycle, improving sleep, and coping with social-emotional issues.
Study NCT03551847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: The intervention involves giving an infected patient antibiotics.
Study NCT03551847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No antibiotics
Description: The intervention involves not giving an infected patient antibiotics.
Study NCT04470973 — intervention group
Intervention type: DRUG
Intervention: Cefuroxime
Description: Patients receive cefuroxime as part of standard care.
Study NCT04470973 — intervention group
Intervention type: DRUG
Intervention: Amikacin
Description: Patients receive amikacin as part of standard care.
Study NCT05329857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Vildagliptin 1000/50 mg
Description: 50 mg Vildagliptin + 1000 mg Metformin as single-dose per study period
Study NCT05329857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Vildagliptin 1000/50 mg
Description: 50 mg Vildagliptin + 1000 mg Metformin as single-dose per study period
Study NCT02970955 — intervention group
Intervention type: PROCEDURE
Intervention: Inoperable thoracic nodes metastases
Description: The radiation treatment will be delivered with three possible schedules, with a risk adaptive scheme according to number, site and size of metastatic nodes and based on the possibility to respect the constraints of healthy tissues
Study NCT03804268 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle, one drop in each eye, once daily, for up to 30 days.
Study NCT03804268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine HCl Ophthalmic Solution
Description: Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
Study NCT03906812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemetry
Description: Bed type assignment
Study NCT03906812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unmonitored
Description: Bed type assignment
Study NCT03037515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: To identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion in lumbar spine surgery.
Study NCT02461537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAM
Description: High-dose cytarabine 1 - 3 g/m2 (days 1-3)/Mitoxantrone 20 mg/m2 (days3-5)
Study NCT02461537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDAC and/or Mitoxantrone
Description: Low-dose cytarabine 20 mg/m2 (days 1-10) and/ or mitoxantrone 10mg/m2 (max 3 doses)
Study NCT03898622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levothyroxine
Description: levothyroxine with a safe dose for our population with high cardiovascular risk of 0.25mcg so that the patient's weight range between 50-80kg maintains a dosage of 0.3-0.5mcg / kg / day that does not affect the thyroid axis) fasting levothyroxine (in the case of taking a drug that interacts with absorption, use of it is changed according to the specified hours, see Table 2), and adjusted according to TSH levels > 1 and normal T4L
Study NCT03898622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: levothyroxine with a safe dose for our population with high cardiovascular risk of 0.25mcg so that the patient's weight range between 50-80kg maintains a dosage of 0.3-0.5mcg / kg / day that does not affect the thyroid axis) fasting levothyroxine (in the case of taking a drug that interacts with absorption, use of it is changed according to the specified hours, see Table 2), and adjusted according to TSH levels > 1 and normal T4L
Study NCT04838002 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave
Description: Focus and Radial types Extracorporeal shock wave therapy
Study NCT04838002 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal shock wave
Description: Focus and Radial types Extracorporeal shock wave therapy
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib will be administered orally at the label-recommended dose (600 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib will be administered orally at the label-recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered orally at the label-recommended dose (400 mg) once daily on Days 1-21 of each 28-day Cycle in combination with paclitaxel, and as monotherapy after the final administration of paclitaxel, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered orally at the label-recommended dose (400 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered orally in combination with Bevacizumab at the label recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously at 15mg/kg every 3 weeks in combination with Erlotinib until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be administered orally, 960 mg twice daily, in combination with Cobimetinib, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered orally, 60mg once daily, in combination with Vemurafenib, on Days 1-21 of each 28-day Cycle, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Subcutaneous (SC)
Description: Trastuzumab will be administered subcutaneously, 600 mg every 3 weeks, in combination with Pertuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Study NCT03440957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic treatment
Description: The patients meeting the inclusions criteria will be informed of the study and an osteopathic treatment holistic ,involving all the body will be applied, three time with 2 days between the treatments .Each meeting with the practitioner will last around 40 minutes. The pain and symptoms assessment will be done before and after the treatment .
Study NCT02613377 — intervention group
Intervention type: OTHER
Intervention: Blood transfusion
Study NCT03668639 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Akynzeo
Description: Weekly administration of akynzeo for five weeks.
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab Subcutaneous (SC)
Description: Trastuzumab will be administered subcutaneously, 600 mg every 3 weeks, in combination with Pertuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be initially be administered intravenously, 840 mg, followed by 420 mg every 3 weeks, in combination with Trastuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab will be initially be administered intravenously, 840 mg, followed by 420 mg every 3 weeks, in combination with Trastuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously at the label-recommended dose (1200 mg), alone or in combination with chemotherapy, every 3 weeks until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered intravenously at the area under the curve (AUC) dose once every 3 weeks for up to 9 Cycles (Cycle = 21 days) in some combination with the following: Paclitaxel, Gemcitabine, Atezolizumab, Pertuzumab, and Trastuzumab SC.
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously, 175 mg/m\^2, once every 3 weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Carboplatin, Ipatasertib, Atezolizumab, Pertuzumab, and Trastuzumab SC
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously, 175 mg/m\^2, once every 3 weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Carboplatin, Ipatasertib, Atezolizumab, Pertuzumab, and Trastuzumab SC
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously, 60-75 mg/m\^2, once every three weeks, for up to 9 cycles (Cycle = 21 days) in some combination with the following: Gemcitabine, Paclitaxel, Atezolizumab, Pertuzumab, and Trastuzumab SC.
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously, 1000 mg/m\^2, twice every three weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Cisplatin, Carboplatin, Atezolizumab, Pertuzumab, and Trastuzumab SC.
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Entrectinib will be administered orally at the label-recommended dose (600 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Ivosidenib will be administered orally at the label-recommended dose (500mg) once daily across a 28-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
Study NCT03498521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib will be administered orally at the label-recommended dose (13.5mg) once daily across a 21-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
Study NCT03365661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: A reduced intensity conditioning starts on Day -6, (CY/FLU/TBI/TLI) followed by infusion of a TCRα/β-deplete haploidentical graft on Day 0. Two doses of ALT-803 are given initially (early) 1 week apart to facilitate NK cell expansion. ALT-803 maintenance (late) for immune reconstitution begins at Day 42 and consists of 4 weekly doses, followed by 4 weeks off. Up to four 8 week treatment courses are permitted. No post-transplant GVHD prophylaxis is administered unless the final donor cell product contains > 2 x 105 α/β T cells/kg recipient weight.
Study NCT02849587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will smoke a cannabis cigarette ad libitum as per their usual routine
Study NCT02849587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis
Description: Participants will smoke a cannabis cigarette ad libitum as per their usual routine
Study NCT01710020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 10 mg oral powder for constitution
Study NCT02658266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home based resistance training
Description: The participants in the intervention group will receive an individualized resistance training program. The individual adjustments in load will will be made from the results of the muscle function and muscle strength tests. The resistance training will be home based and performed 3 times per week 10-12 reps 2 sets 12 weeks. Increment of load will be performed continuously according to rating of perceived exertion.
Study NCT02208544 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diagnostic Thyroid Surgery
Description: Diagnostic Thyroid Surgery